louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02890394: Effectiveness of the Suboccipital Inhibition Technique in Patients With Mechanical Neck Pain
Official title: Effectiveness of the Suboccipital Inhibition Technique in Patients With Mechanical Neck Pain: a Pilot Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Neck Pain
Myofascial Pain
Keywords: Neck Pain
Suboccipital inhibition
Physical Therapy
Lead sponsor: University of Alcala
Sponsor class: OTHER
First posted: 2016-09-07
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The project is based on checking the effectiveness of the technique of suboccipital inhibition in patients with mechanical neck pain. Suboccipital inhibition technique involves the placement of the hands of the physiotherapist under the patient's head so that fingers can feel the spinous processes of the cervical vertebrae. Then the fingers slowly leads upward to contact the occipital condyles. At this point the investigator should gently move your fingers down, finding the space between the condyles and the spinous process of the axis. Then, flexing the metacarpophalangeal joints at 90 degrees, slowly raises the skull. In this technique the investigator would be carrying out the relaxation of the suboccipital muscles: lower rectus capitis posterior, superior oblique head straight back and head higher. It is a technique used very often but without knowledge about the time needed for implementation. In several studies that have used the technique it has been maintained for 2.4 or 10 minutes without agreeing how long is necessary. The study will consist of three groups formed by patients with mechanical neck pain that they applied the technique two, four or ten minutes and a control group of patients with mechanical neck pain. The four groups were measured before and after treatment the pain threshold to pressure by algometer and conduct the test repositioning of the head to show any changes after application of the technique.


Eligibility criteria: Inclusion Criteria:

1. Men and women of full age .
2. ≥ 15/50 rating in the Neck Disability Index
3. Participants with good adhesion to the study .
4. Participants who have signed informed after appropriate informed consent.

Exclusion Criteria:

1. Cancer , inflammatory , infectious , vascular , neurological and metabolic processes.
2. Patients who are under medical treatment.
3. Patients with psychiatric illnesses.
4. Women : pregnancy.
5. Patients who have not signed the informed consent.

Primary outcomes:
measure: Change from pain threshold pressure after ten minutes from the suboccipital inhibition
timeFrame: It is measured at the beginning of the study. After ten minutes from the suboccipital inhibition is remeasured
measure: Change from repositioning of the head after ten minutes from the suboccipital inhibition
timeFrame: It is measured at the beginning of the study. After ten minutes from the suboccipital inhibition is remeasured
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02276794: Thrust Versus Non-thrust Manipulation in Chronic Low Back Pain
Official title: The Effects of Thrust Versus Non-thrust Manipulation on Pain, Trunk Proprioception and Postural Stability in Subjects With Chronic Low Back Pain
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Low Back Pain
Mechanical Low Back Pain
Backache
Keywords: Low back pain
Thrust manipulation
Spinal manipulation
Joint mobilization
Non-thrust manipulation
proprioception
Postural stability
Baropodometry
Lead sponsor: Federal University of Health Science of Porto Alegre
Sponsor class: OTHER
First posted: 2014-10-28
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to verify the effects of Thrust Versus Non-thrust Manipulation on Pain, Trunk Proprioception and Postural Stability in Subjects With Chronic Low Back Pain.

Detailed description: Forty individuals with chronic low back pain will be randomly assigned, by a researcher not involved in data collection, to two treatment groups: Thrust manipulation (side-lying rotational manipulation standardized to the L4-L5 level) or non-thrust manipulation (side-lying grade III rotational non-thrust manipulation). A single treatment session will be provided.

Outcome measurement will be conducted immediately after the treatment session. Data will be collected by a blinded assessor. Between-group differences will be calculated by constructing mixed linear models following an intention-to-treat principle.

Eligibility criteria: Inclusion Criteria:

* Age greater than 18 years
* Chronic Low back pain (pain lasting for at least 12 weeks)
* NPRS ≥ 3

Exclusion Criteria:

* Previous surgery or fracture at the lumbar spine
* Pregnancy
* Inflammatory disorders
* Symptoms distal to the gluteal line
* Having received manipulative treatment in the past four weeks

Primary outcomes:
measure: Pain
timeFrame: Up to 10 minutes after intervention
Secondary outcomes:
measure: Global Perceived Effect
timeFrame: Up to 10 minutes after intervention
measure: Lumbar joint position sense
timeFrame: Up to 10 minutes after intervention
measure: Peak plantar pressure
timeFrame: Up to 10 minutes after intervention
measure: Center of Pressure displacement
timeFrame: Up to 10 minutes after intervention
Other outcomes:
measure: Foot contact area
timeFrame: Up to 10 minutes after intervention
Locations:
city: Porto Alegre
country: Brazil
facility: Federal University of Health Sciences of Porto Alegre
state: Rio Grande do sul
Study officials:
affiliation: Adjunct professor
name: Marcelo F Silva, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT06380894: Virtual Reality Cognitive Training for Mild Cognitive Impairment
Official title: Virtual Reality Cognitive Training for Mild Cognitive Impairment - A Pilot Feasibility Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mild Cognitive Impairment
Lead sponsor: Changi General Hospital
Sponsor class: OTHER
First posted: 2024-04-24
Enrollment: 20
Sex: ALL
Minimum age (years): 65
Maximum age (years): 85
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study aims to assess the feasibility and efficacy of a 10-weekly multi-domain VRCT program on the cognitive function (i.e. attention, memory, and executive functioning) of older adults with MCI.

Detailed description: This study employed a pilot feasibility parallel design approach. Participants were randomly assigned to either the VRCT intervention group or the active control group. The outcome assessor was blinded. Participants were recruited from outpatient clinics in Changi General Hospital, Singapore. They were referred by treating geriatricians and psycho-geriatricians.

Eligibility criteria: Inclusion Criteria:

* aged 65-85
* diagnosis of MCI by a clinician in accordance to Petersen's criteria
* MMSE ≥ 23
* ability to see and hear
* ability to read and write in either English or Mandarin

Exclusion Criteria:

* diagnosed with a primary other neurocognitive disorder
* diagnosed with major psychiatric illness such as major depressive disorder or anxiety disorder, severe visual or auditory impairment
* diagnosed with serious medical illnesses including acute or severe asthma, severe or unstable cardiovascular disease, active gastric ulcer, severe liver disease or severe renal disease.

Primary outcomes:
measure: Change from Baseline in Memory Performance on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) subtests at Week 11
timeFrame: Baseline and Week 11
measure: Change from Baseline in Attention Performance on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) subtest at Week 11
timeFrame: Baseline and Week 11
measure: Change from Baseline in Attention Performance on the Colour Trails Test 1 at Week 11
timeFrame: Baseline and Week 11
measure: Change from Baseline in Executive Function Performance on the Frontal Assessment Battery (FAB) at Week 11
timeFrame: Baseline and Week 11
measure: Change from Baseline in Executive Function Performance on the Colour Trails Test 2 at Week 11
timeFrame: Baseline and Week 11
Secondary outcomes:
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Changi General Hospital
Study officials:
affiliation: Changi General Hospital
name: Zhong Jie Zaylea Kua, MPsychClin
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06484894: The Effect of Refractive Errors on Central Corneal Thickness by Using Pentacam and IOL Master
Official title: The Effect of Refractive Errors on Central Corneal Thickness by Using Pentacam
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Central Corneal Thickness
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-07-03
Enrollment: 50
Sex: ALL
Minimum age (years): 20
Maximum age (years): 41
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. Inclusion criteria:

   Subjects included in this study aged between20 and 41 asked for refractive surgery
2. Exclusion criteria:-

   * Severe corneal scarrig or opacification., dystrophy
   * Patients with history of recent contact lens Ocular trauma.
   * Uveitis patients Patients with keratoconus.
   * Previous ocular or refractive surgey

Brief summary: To evaluate the impact of refractive errors on the central corneal thickness obtained by Pentacam and intraocular lenses (IOL) master in eyes with different refractive errors.

Detailed description: Central corneal thickness (CCT) is a key indicator of corneal health status and helps to assess corneal diseases. The normal corneal thickness is about 540 μm and mainly consists of the stroma, which is estimated at 450 μm in the center. The stroma provides vital structural integrity and plays a key role in helping maintain transparency. It has been reported, however, that CCT follows a diurnal pattern being 10 μm thicker in the morning due to reduced evaporation of water from underneath the closed eyelids

Eligibility criteria: Inclusion Criteria:

* Subjects included in this study aged between20 and 41 years, asked for refractive surgery

Exclusion Criteria:

* patients with corneal scarrig or opacification.

  * Patients with corneal dystrophies.
  * Patients with keratoconus.
  * Previous ocular or refractive surgery.
  * Ocular trauma.
  * Uveitis patients.
  * Patients with history of recent contact lens wear.

Primary outcomes:
measure: To find if there a correlation between refractive errors and the central corneal thickness
timeFrame: Baseline
Secondary outcomes:
measure: To study if there a difference between measurement by pentacam and measurement of IOL master
timeFrame: Baseline
Other outcomes:
Locations:
Study officials:
affiliation: Assiut University
name: Mahmoud Fathy rateb, Professor
role: STUDY_DIRECTOR
affiliation: Assiut University
name: Ahmed Abd el Nasser awad, Lecturer
role: STUDY_CHAIR
affiliation: Assiut University
name: Mohamed Tarek Abd el menaam, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wang Q, Liu W, Wu Y, Ma Y, Zhao G. Central corneal thickness and its relationship to ocular parameters in young adult myopic eyes. Clin Exp Optom. 2017 May;100(3):250-254. doi: 10.1111/cxo.12485. Epub 2016 Oct 18.
citation: Prasad A, Fry K, Hersh PS. Relationship of age and refraction to central corneal thickness. Cornea. 2011 May;30(5):553-5. doi: 10.1097/ICO.0b013e3181fb880c.
Clinical trial NCT04204694: Study of the Role of Interferon αon the Endothelial Dysfunction During Septic Shock
Official title: Study of the Role of Interferon αon the Endothelial Dysfunction During Septic Shock
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Septic Shock
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2019-12-19
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will have two groups :

1. Patients with septic shock hospitalized in the ICU from Strasbourg University Hospital
2. Controls: blood donors recruited by the French blood establishment

Brief summary: Septic shock is the most severe form of a bacterial infection, affecting 24 million patients per year worldwide, with a high mortality (\> 30%).

Septic shock is defined by an acute circulatory failure, with low blood pressure and insufficient oxygen supply to organs. This circulatory failure is related to vascular damages, in which the endothelial vascular tissue is impaired by inflammatory mechanisms, with release of circulating endothelial cells in the blood.

Therefore, modulating inflammation on the vascular endothelial tissue could be a therapeutic strategy, and the investigators focus on the role of the type I interferons on the endothelial tissue because of the demonstrated role of type I interferons during septic shock.

Thus the investigators proceed to an observational study, in which the primary purpose will be to show a higher expression of type I interferon receptors on circulating endothelial cells in patients with septic shock compared to control subjects.

Concerning secondary purposes, the investigators will record mortality at d3, d7 and d28, perform assays about types I, II and III interferons in plasma, and test anti-interferon on endothelial cells ex vivo


Eligibility criteria: * For all subjects
* Age \> 18 years old
* For females: negative pregnancy test
* Subject covered by health insurance
* Written consent
* Patients with septic shock
* Patients must be in ICU
* Septic shock defined by the Sepsis-3 criteria \[1\]
* Inclusion within the 12 hours following the onset of norepinephrin
* Controls :
* Blood donors

Exclusion criteria:

* Moribund
* Age \< 18 years old
* Absence of written consent

Primary outcomes:
measure: Expression of the activated interferon-α receptors (IFNAR) by circulant endothelial cells
timeFrame: Within 12 hours following the onset of norepinephrin for septic shock (day 1)
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de réanimation médicale
Study officials:
References:
Clinical trial NCT02895594: Outcome of Surgery for Idiopathic Macular Holes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Idiopathic Macular Hole
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2016-09-09
Enrollment: 59
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients treated by retinal repair surgery for idiopathic macular hole

Brief summary: Retrospective medical chart review of patients undergoing surgical repair of idiopathic macular hole


Eligibility criteria: Inclusion Criteria:

* Patient suffering from primary idiopathic macular hole and treated by retinal repair surgery

Exclusion Criteria:

* Presence of other retinal disease

Primary outcomes:
measure: Primary closure of macular hole after repair surgery
timeFrame: within six months after surgery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04555694: Comparing Treatment of Dry Eye With Intracanalicular Dexamethasone, Restasis, and/or Lotemax
Official title: Intracanalicular Dexamethasone Used in Conjunction With Restasis (Cyclosporine Ophthalmic Emulsion) for the Treatment of Signs and Symptoms of Dry Eye Disease as Compared to Restasis With Lotemax (Loteprednol Etabonate Ophthalmic Suspension 0.5%) and Restasis Monotherapy.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Dry Eye
Lead sponsor: Cleveland Eye Clinic
Sponsor class: OTHER
First posted: 2020-09-21
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 10 subjects will receive Restasis and Dextenza 10 subjects will receive Restasis and Lotemax 10 subjects will receive Restasis
Primary purpose: TREATMENT

Brief summary: This 6 month study seeks to compare the use of Intracanalicular Dexamethasone in conjunction with Restasis (cyclosporine ophthalmic emulsion) for the treatment of signs and symptoms of dry eye disease as compared to Restasis with Lotemax (loteprednol etabonate ophthalmic suspension 0.5%) and Restasis monotherapy.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* Signs and symptoms of Dry Eye Disease
* Consent to treat with topical immunomodulator
* Willing and able to comply with clinic visits and study related procedures
* Willing and able to sign the informed consent form

Exclusion Criteria:

* Patients under the age of 18.
* Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)
* Active infectious systemic disease
* Active infectious ocular or extraocular disease
* Altered nasolacrimal flow of either acquired, induced, or congenital origin
* Hypersensitivity to dexamethasone
* Patients who have been on topical immunomodulating agents in the previous 3 months to their baseline visit
* Patient being treated with either topical, oral, or intravenous immunosuppressive agents, immunomodulating agents, or steroid (including NSAIDS)
* Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator

Primary outcomes:
measure: Mean Ocular Surface Staining From Baseline
timeFrame: Baseline to Week 4, Week 8 and Week 12
Secondary outcomes:
measure: Mean Conjunctival Staining
timeFrame: Baseline to Week 4, Week 8 and Week 12
measure: Mean Schirmer Tear Test 1 Score
timeFrame: Baseline to Week 4, Week 8 and Week 12
measure: Tear Breakup Time (Seconds)
timeFrame: Baseline to Week 4, Week 8 and Week 12
measure: Tear Osmolarity
timeFrame: Baseline to Week 4, Week 8 and Week 12
measure: Meibomian Gland Scores
timeFrame: Baseline to Week 4, Week 8 and Week 12
measure: DEQ-5 Score
timeFrame: Baseline to Week 4, Week 8 and Week 12
Other outcomes:
Locations:
city: Brecksville
country: United States
facility: Cleveland Eye Clinic
state: Ohio
Study officials:
References:
Clinical trial NCT00988494: Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect
Official title: Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Persistent Corneal Epithelial Defect
Lead sponsor: Santen Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2009-10-02
Enrollment: 45
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Safety and efficacy of DE-105 ophthalmic solution in patients with persistent corneal epithelial defect will be evaluated. Dose-dependent efficacy will be evaluated as well.


Eligibility criteria: Inclusion Criteria:

* Has corneal epithelial defect and decreased corneal sensitivity.
* Has undergone continuous treatment for corneal epithelial defect for 1 week or longer.

Exclusion Criteria:

* Presence of disease such as active ocular infection, or abnormal lid closure.
* History or presence of chemical burn, Stevens - Johnson Syndrome, etc.
* History of corneal transplantation, LASIK, or hematopoietic stem cell transplantation.

Primary outcomes:
measure: Restoration of corneal epithelial defect
timeFrame: Every week
Secondary outcomes:
measure: Visual acuity,etc.
timeFrame: Exit visit,etc.
Other outcomes:
Locations:
city: Osaka
country: Japan
facility: Santen study sites
Study officials:
References:
Clinical trial NCT05620394: Study of the Geometry of the Immature Human Femur Before the Age of 3 Years From Data Measured on CT Scan
Official title: Study of the Geometry of the Immature Human Femur Before the Age of 3 Years From Data Measured on CT Scan
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Femur Fracture, Childhood
Keywords: Femur Fracture, Childhood
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2022-11-17
Enrollment: 150
Sex: ALL
Maximum age (years): 3
Standard ages: CHILD
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Minor patient who died before the age of 3 years

Brief summary: Childhood fractures are the second most common presentation of abuse. The target population for screening for these injuries is children under the age of three who are unable to express themselves about the circumstances of the trauma, hence the need to develop a validated model to predict the outcome of trauma as well as the origin of a fracture.

Few morphological data are available in the literature for the femur concerning the period of rapid growth between 0 and 3 years of age.


Eligibility criteria: Inclusion criteria:

* Minor patient who died before the age of 3 years
* Whole body CT imaging performed post mortem on judicial requisition in the framework of a forensic procedure
* Absence of refusal in the medical file by the holders of parental authority concerning the re-use of their child's data for the purposes of this research

Exclusion criteria:

* Refusal manifested in the medical record by parental authority holders regarding the reuse of their child's data for the purpose of this research,
* Femur not fully assessable on imaging acquisition

Primary outcomes:
measure: To retrospectively characterize the variations in femur morphology during growth in a target pediatric population aged 0 to 3 years
timeFrame: Files analysed retrospectively from January 01, 2015 to February 29, 2020 will be examined
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service de Médecine Légale et Toxicologie - CHU de Strasbourg - France
Study officials:
References: